{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Marinac CR"],"funding":["SU2C","NCI NIH HHS","American Society of Hematology","NCI NIH NCI","NCI NIH"],"pagination":["479-485"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8825752"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(2)"],"pubmed_abstract":["<h4>Background</h4>Inflammation is important in multiple myeloma pathogenesis, and regular aspirin use has been shown to confer a reduced risk of multiple myeloma. The influence of aspirin on survival after multiple myeloma diagnosis is unknown.<h4>Methods</h4>We identified 436 men and women diagnosed with multiple myeloma between 1980 and 2016 in the Health Professionals Follow-up Study and the Nurses' Health Study who reported aspirin intake biennially on follow-up questionnaires. Using multivariable Cox proportional hazards regression models, we estimated HRs and 95% confidence intervals (CI) associated with the effect of aspirin use on multiple myeloma-specific and overall mortality.<h4>Results</h4>Compared with nonusers, participants who used aspirin after diagnosis had a multivariabl"],"journal":["Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"],"pubmed_title":["Regular Aspirin Use and Mortality in Patients with Multiple Myeloma."],"pmcid":["PMC8825752"],"funding_grant_id":["PF-17–231–01-CCE","K07 CA115687","F32 CA220859","R03 CA204825","U01 CA167552","P01 CA87969","P01 CA087969","AACR-DT-28-18","R21 CA198239","R01 CA127435","K22 CA251648","UM1 CA186107"],"pubmed_authors":["Ghobrial IM","Lee DH","Colditz GA","Marinac CR","Rosner B","Birmann BM","Bustoros M","Rebbeck TR"],"additional_accession":[]},"is_claimable":false,"name":"Regular Aspirin Use and Mortality in Patients with Multiple Myeloma.","description":"<h4>Background</h4>Inflammation is important in multiple myeloma pathogenesis, and regular aspirin use has been shown to confer a reduced risk of multiple myeloma. The influence of aspirin on survival after multiple myeloma diagnosis is unknown.<h4>Methods</h4>We identified 436 men and women diagnosed with multiple myeloma between 1980 and 2016 in the Health Professionals Follow-up Study and the Nurses' Health Study who reported aspirin intake biennially on follow-up questionnaires. Using multivariable Cox proportional hazards regression models, we estimated HRs and 95% confidence intervals (CI) associated with the effect of aspirin use on multiple myeloma-specific and overall mortality.<h4>Results</h4>Compared with nonusers, participants who used aspirin after diagnosis had a multivariabl","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2025-04-04T19:40:34.867Z","creation":"2025-04-04T19:40:34.867Z"},"accession":"S-EPMC8825752","cross_references":{"pubmed":["34862208"],"doi":["10.1158/1055-9965.epi-21-0946","10.1158/1055-9965.EPI-21-0946"]}}